177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 Years' experience from a tertiary cancer care centre in India

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1319-1326

  Danthala, Madhav ^a   Kallur, K G ^a   Prashant, G R ^a   Rajkumar, K ^a   Raghavendra Rao, M ^a  

^a HCG Hospital   (India)

Author keywords

NET neuroendocrine tumours; PRRT peptide receptor radionuclide therapy

Indexed keywords

1 4 7 10 TETRAAZACYCLODODECANE 1 4 7 10 TETRAACETATE TYROSINE OCTREOTATE LU 177; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; DOXORUBICIN; GELATIN SUCCINATE; IODINATED POPPYSEED OIL; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROENDOCRINE TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; MIDDLE AGED; NEUROENDOCRINE TUMORS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL; TERTIARY CARE CENTER;

ADULT; AGED; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS;

EID: 84903729500     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2710-1     Document Type: Article

References (28)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
2. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:3-7.
3. De Herder WW, Hofland LJ, Van der Lely AJ, Lamberts SWJ. Somatostatin receptors in gastro-entero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451-8. (Pubitemid 38094881)
4. De Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42(7):873-80.
5. Sward C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, et al. Comparison of [177Lu-DOTA0, Tyr3]-octreotate and [177Lu-DOTA0, Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm. 2008;23(1):114-20. (Pubitemid 351304215)
6. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406-16. (Pubitemid 47067899)
7. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller- Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):968-76.
8. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30.
9. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28(9):1319-25.
10. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)] octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33(11):1346-51. (Pubitemid 44630791)
11. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-16.
12. Bodei L, CremonesiM, GranaCM, Fazio N, Iodice S, BaioSM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125-35.
13. Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116 Suppl 4:1084-92.
14. Hörsch D, Ezziddin S,HaugA,GratzKF, Dunkelmann S,Krause BJ, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. In: Baum RP, Rösch F, editors. Theranostics, gallium-68, and other radionuclides. Berlin: Springer; 2013. p. 457-65.
15. Kunikowska J, Królicki L, Sowa-Staszczak A, Hubalewska-Dydejczyk A, Pawlak D, Mikolajczak R, et al. Polish experience in peptide receptor radionuclide therapy. In: Baum RP, Rösch F, editors. Theranostics, gallium-68, and other radionuclides. Berlin: Springer; 2013. p. 467-78.
16. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3] octreotate. J Clin Oncol. 2004;22(13):2724-9. (Pubitemid 41103761)
17. de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617-20.
18. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. (86YDOTA0)-DPhe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-8. (Pubitemid 36559829)
19. Irina R, Robert R, Walter K, Rosemany D, Wendy G. Hepatic artery embolization with combined 131-I-lipiodol and doxorubicin/cisplatin as local radiosensitizers for the treatment of neuroendocrine tumour (NET) liver metastases. J Nucl Med. 2006;47 Suppl 1:105P.
20. Natasha S, Krishna BA, Madhusudhan V, Meera V, Sharmila B, Tapas D, et al. Lutetium DOTATATE whole body scans: a novel approach for evaluation of neuroendocrine tumours. Indian J Nucl Med. 2011;26(3):135-8.
21. Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patientswith inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38(9):1669-74.
22. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51(3):383-90.
23. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D,Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-12.
24. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9:261-7.
25. Hajarizadeh H, Ivancev K,Mueller CR, FletcherWS,Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg. 1992;163:479-83.
26. Gupta S, JohnsonMM,Murthy R, AhrarK,WallaceMJ,Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer. 2005;104(8):1590-602. (Pubitemid 41437421)
27. Seregni E,MaccauroM, Coliva A, CastellaniMR, Bajetta E, Aliberti G, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.Q J NuclMed Mol Imaging. 2010;54(1):84-91.
28. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788-97.